On this basis, we hypothesized that inhibiting Mcl-1 by NSC260594 could improve everolimus-induced apoptosis in TNBCs, and the combination of NSC260594 and everolimus could provide synergistic effects in tumor-killing activity. Here, MCL1 is linked to neoplasm.